



Chair's Address

Good morning, everyone, and thank you for joining us today.

On behalf of the Board, I want to start by thanking you, our shareholders, for your continued support of Imricor. Your belief in our vision has been instrumental in getting us to this point, and we deeply value the trust and confidence you have placed in us.

2025 was a defining year for Imricor. It was a year in which we continued to move from promise to execution. We made important progress across our clinical, regulatory, commercial, and operational priorities, all with one objective in mind: to establish interventional MR as a new standard of care.

During the year, we advanced our U.S. regulatory pathway, continued to progress the VISABL-AFL clinical trial, expanded our clinical footprint, and deepened engagement with leading hospitals and physicians who see the same future we do, a future where electrophysiology procedures are performed with real-time soft tissue visualization, without ionizing radiation, and with the potential for greater precision and better outcomes. We also took a significant leap forward with the world's first ventricular tachycardia ablation performed in the MR environment. VT ablation is one of the most complex procedures in electrophysiology, and this milestone clearly demonstrated that our platform is ready for some of the most challenging ablations in cardiac care.

We also continued to build momentum in Europe, where our technology is already being used in leading centers. These sites are not only treating patients, they are helping demonstrate what is possible when cardiac procedures are performed in a cath lab that has replaced X-ray imaging with the advanced imaging of magnetic resonance.

One of the most exciting developments of the year was the growing recognition that Imricor is not simply building a better catheter. We are building a platform. Our devices, our capital equipment, and our NorthStar mapping system are designed to work together as a complete integrated ecosystem for interventional MR. That platform approach is what gives us the opportunity to expand beyond a single procedure, beyond a single indication, and ultimately beyond electrophysiology.

The milestones achieved in 2025 were the result of many years of persistence. Imricor has been working toward this moment for nearly two decades. We have had to solve problems that others considered too difficult. We have had to build technology, clinical evidence, regulatory pathways, and physician confidence, often all at the same time. That is hard work. But it is also what creates enduring value.

Importantly, we now enter the next phase with a stronger balance sheet. Thanks to you, our shareholders, Imricor has the capital needed to execute from a position of strength. We intend to invest that capital wisely and with discipline. Our priorities are clear: strengthen our commercial capabilities, expand our installed base, advance our regulatory approvals, support our clinical trials, and bring Interventional MR to hospitals, physicians, and patients around the world.

The opportunity in front of us is significant. The electrophysiology market is very large and growing, and physicians are demanding better capabilities to improve patient care and increase



efficiency, all while they are trying to remove X-ray radiation as a part of their daily lives. Patients deserve this better treatment, and medical personnel deserve a safe and efficient work environment. Imricor is uniquely positioned to deliver that future.

To our employees, thank you for your dedication and belief. To our physicians and hospital partners, thank you for your courage and leadership. To our Board, thank you for your guidance. And to our shareholders, thank you for supporting us as we work to transform the way cardiac procedures are performed.

I believe we are standing at the threshold of a new era in medicine. *Imricor's Interventional MR, or "iMR" solution, offers a different future.* A future with real-time visualization of anatomy and tissue characteristics. A future without ionizing radiation. A future where physicians can see more, know more, and do more for their patients.

That is the future Imricor was created to bring to the world; and together. That is what we are doing. We are Interventional MR. We are iMR.

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO

Media and Investor Relations Contacts:

Simon Hinsley
Executive Director, NWR
simon@nwrcommunications.com.au
+61 401 909 653

Nick Corkill
VP Corporate Strategy, Imricor
nick.corkill@imricor.com
+61 450 475 633

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance (MR) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MR's superior imaging capabilities.

Imricor's Products

Imricor is a pioneer and world leader in developing MR-compatible products for cardiac catheter ablation procedures. The Company's products include capital equipment, such as the NorthStar® Mapping System and the Advantage-MR® EP Recorder/Stimulator. Single-use devices include a variety of ablation catheters, diagnostic catheters, steerable sheaths, and other tools used for cardiac ablations.

Imricor's products are approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand. NorthStar is approved in the US.

Foreign Ownership Restrictions

Imricor's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons excluding qualified institutional buyers (QIBs, as defined in Rule 144A under the Securities Act). However, you are still able to freely transfer your CDIs on ASX to any person other than a US



person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For personal use only